Pulmonary embolism (PE) is a serious and life-threatening condition caused by blockage of the pulmonary arteries by a blood clot, usually originating in the deep veins of the legs (deep venous thrombosis). It is a leading cause of death worldwide and the median cause of emergency department visits. PE may present with a variety of clinical symptoms, including dyspnea, chest pain, tachycardia, and cyanosis. Importantly, early diagnosis and treatment are vital to reduce mortality and improve outcomes.
History of the disease and interesting historical facts
The history of pulmonary embolism research dates back to the late 17th century, when the association between thrombosis and the development of pulmonary embolism was first observed. Scientists such as Galen and Hippocrates discussed the symptoms of diseases associated with vascular obstruction, although the exact mechanisms remained unknown. In the late 19th century, the eminent pathologist Rudolf Virchow described a triad of factors that promote thrombus formation, known as the Virchow triad. In the early 20th century, the use of vitamin K antagonists and anticoagulants became the basis for treating this condition. In recent decades, with the development of medical technologies such as computed tomography, the detection of PE has become more accurate and rapid.
Epidemiology
Pulmonary embolism is an important morbidity and mortality risk worldwide. According to various data, the annual incidence of PE ranges from 5 to 70 per 100,000 population, depending on the population and country. In developed countries, PE is considered the third most common cause of cardiovascular disease after myocardial infarction and stroke. It has also been found that about 25% patients with severe PE die within an hour of symptom onset, which emphasizes the need for immediate treatment of this pathology. Meta-analyses show that in hospitalized patients with risk factors, the risk of developing PE may increase to 40%.
Genetic predisposition to this disease
There are certain genetic factors that may predispose to the development of pulmonary embolism. In particular, known mutations in the hemostatic proteins, such as mutations in the factor V Leiden and protein C genes, may contribute to thrombosis. The factor V Leiden mutation occurs in the 5% population and increases the risk of developing venous thrombosis. Other important genes involved in venous thromboembolism include genes responsible for the synthesis of anticoagulants, such as antiphospholipid syndrome, which ensures the development of thrombosis even in the absence of obvious provoking factors. According to statistics, a familial predisposition to thrombosis can be found in 50% cases.
Risk factors for the development of this disease
There are many risk factors that can contribute to the development of pulmonary embolism. The following key factors are identified:
- Physical factors:
- Limited mobility: prolonged periods of immobility, such as after surgery or long journeys.
- Trauma: Bone fractures, especially in the lower extremities, can contribute to tremor formation.
- The presence of varicose veins.
- Chemical factors:
- Taking oral contraceptives and hormonal therapy.
- Smoking, which contributes to damage to the vascular wall.
- Conditions accompanied by hypercoagulation: oncological diseases, infectious processes.
- Other factors:
- Age over 60 years.
- Family history of thromboembolism.
Diagnosis of this disease
Diagnosis of pulmonary embolism requires a comprehensive approach, including assessment of clinical symptoms and the use of various examination methods.
- Main symptoms:
- Shortness of breath, often sudden.
- Chest pain that may worsen with deep breathing.
- Cough, sometimes with blood.
- Tachycardia or arrhythmia.
- Laboratory tests:
- Complete blood count to determine D-dimer levels.
- Coagulogram to assess hemostasis.
- Biochemical analysis to identify concomitant diseases.
- Radiological examinations:
- Contrast-enhanced CT is the "gold standard" for diagnosing PE.
- Magnetic resonance imaging (MRI) is less commonly used but may be useful in limited circumstances.
- Lung scintigraphy to assess pulmonary perfusion flow.
- Other types of diagnostics:
- Ultrasound examination of the veins of the lower extremities to detect blood clots.
- ECG to rule out acute coronary syndrome.
- Differential diagnosis:
- It is necessary to distinguish PE from acute coronary syndrome, pneumonia, pleurisy and other diseases.
Treatment
Treatment of pulmonary embolism depends on the severity of the condition and includes several main areas:
- General treatment:
- Vigilance and the earliest possible approach to treatment to reduce the number of fatal outcomes.
- Supportive care, including oxygen therapy if needed.
- Ensuring adequate venous patency.
- Pharmacological treatment:
- Anticoagulants such as warfarin, low molecular weight heparins, and direct oral anticoagulants (eg, rivaroxaban).
- Thrombolytic therapy for massive PE to dissolve the thrombus.
- Surgical treatment:
- Embolectomy is the removal of a blood clot from the pulmonary artery during surgery.
- Placement of filters in the inferior vena cava to prevent thrombus formation.
- Other types of treatment:
- Physiotherapy to restore movement function.
List of medications used to treat this disease
The most commonly used drugs to treat pulmonary embolism include:
- Low molecular weight heparins: enoxaparin, delteparin.
- Direct oral anticoagulants: rivaroxaban, apixaban.
- Warfarin.
- Thrombolytics: streptokinase, alteplase.
- Plasma substitutes and drugs to improve hemodynamics in severe cases.
Disease monitoring
Monitoring of the patient's condition after diagnosis of PE includes regular observation and evaluation of the effectiveness of treatment. The main stages of monitoring are as follows:
- Monitoring D-dimer levels to assess the risk of relapse.
- Regular ultrasound examination of veins to detect recurrent thrombosis.
- Assessment of the patient's functional status and his ability to perform physical activity.
- The prognosis depends on the degree of pulmonary embolism, the presence of concomitant diseases and the adequacy of treatment.
- Oxal complications: risk of developing chronic pulmonary hypertension, recurrent venous thrombosis.
Age-related features of the disease
PE may have different clinical manifestations depending on the age group. In elderly people, the disease may proceed more latent with less pronounced clinical symptoms, which complicates diagnosis. In young patients, PE often causes an acute manifestation and requires rapid intervention. In addition, age-related metabolic features and concomitant pathology (e.g., arterial hypertension, diabetes) also affect the clinical course and outcome of the disease.
Questions and Answers
- What is pulmonary embolism?
Answer: Pulmonary embolism is a condition in which a blood clot that forms in the deep veins blocks the pulmonary arteries, which can lead to serious complications and even death. - What symptoms may indicate PE?
Answer: The main symptoms of PE are shortness of breath, chest pain (which occurs or worsens with breathing), tachycardia, and sometimes coughing up blood. - How is PE diagnosed?
Answer: Diagnosis includes clinical evaluation, laboratory tests such as D-dimer levels, radiological examinations including CT scan and ultrasound of the veins. - What are the main treatments for PE?
Answer: Treatment of PE includes anticoagulant therapy, thrombolytic therapy in severe cases, and surgical interventions if necessary. - What is the prognosis for patients with PE?
Answer: The prognosis depends on the speed of diagnosis and the start of treatment. With timely medical care, survival rates improve significantly.
